Cartalax
/ Khavinson-tradition tripeptide; proposed cartilage bioregulatorALIAS · AED variant (cartilage) · Cartilage peptide bioregulator
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Cartalax is referenced in Khavinson-group review papers as a cartilage-targeted bioregulator within the peptide-bioregulator series. Indexed PubMed primary literature isolating cartalax as the studied agent (rather than mentioning it as one of a panel) is not identifiable.
Cartalax is presented in the Khavinson peptide-bioregulator framework as a short peptide proposed to act on cartilage tissue (chondrocyte proliferation, extracellular-matrix remodelling). The class-level mechanistic hypothesis is sequence-specific DNA binding and transcriptional modulation; cartalax-specific molecular characterisation is absent from indexed primary literature.
Tier 4. No peptide-specific clinical or preclinical study with cartalax as the named agent in indexed PubMed literature. No replicated independent evidence base.
No formal human safety database. No peptide-specific safety record.
Regulatory status
- FDA status:
- Not FDA-approved
Russian-origin literature (Khavinson group, Saint-Petersburg Institute of Bioregulation and Gerontology) without independent Western replication. Cartalax as a distinctly studied compound is essentially absent from the indexed primary record — the cartilage-bioregulator role is asserted in review and product material rather than established by replicated peer-reviewed studies. Vendor sales presume cartilage-specific bioactivity that the published record does not establish.